Analysis of Urea Levels of Banjarmasin Ministry of Health Polytechnic Students Survivors of Covid 19
DOI:
https://doi.org/10.35916/thmr.v5i1.97Abstract
Corona Virus Disease 2019 (Covid-19) is an infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Drug therapy for Covid-19 patients currently uses broad-spectrum antivirals such as Remdesivir, Favipiravir, and Oseltamivir, which have side effects of impaired kidney function with a marked increase in serum urea levels. The study aims to analyze the relationship between antiviral administration and serum urea levels of Covid-19 survivors with student respondents from the Health Polytechnic of the Ministry of Health, Banjarmasin, Indonesia. The research method is an analytic survey with a case-control design. Samples were taken using the purposive sampling method and obtained from 10 respondents who were confirmed positive for Covid-19 who consumed antivirals, ten respondents who were confirmed positive for Covid-19 did not consume antivirals, and ten respondents who were not confirmed positive for Covid-19. The Urea test method uses the Rayto Chemray 120 Clinical Analyzer. The results showed that the average urea level of respondents who confirmed positive for Covid-19 who consumed antivirals was 37.35 mg/dl, and respondents who confirmed positive for Covid-19 who did not consume antivirals was 30.70 mg/dl. Respondents who were not confirmed for Covid-19 19 are 30.97 mg/dl. The study's conclusion showed a relationship between the administration of antivirals and serum urea levels of Covid-19 survivors. Suggestions for further research are to use different parameters in assessing the kidney function of Covid 19 survivors, such as creatinine and blood urea nitrogen.
References
World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (Covid-19). 2020.Geneva: WHO. https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf. Accessed 12-08-2023.
Mao R, Qiu Y, He JS. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5(7): 667-678.
Mishra AK, Sahu KK, George AA, Lal A. A review of cardiac manifestations and predictors of outcome in patients with COVID-19. Heart Lung. 2020; 49(6): 848-852.
Benny R, Khadilkar SV. COVID 19: neuromuscular manifestations. Ann Indian Acad Neurol. 2020; 23(Suppl 1): S40-S42.
Harapan H, Itoh N, Yufika A. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020; 13(5): 667-673
Kementerian Kesehatan RI. Situasi Covid-19 di Indonesia: Jumlah Terpapar Covid-19. 2022. https://covid19.go.id/artikel/2022/04/06/situasi-covid-19-di-indonesia-update-6-april-2022. Accessed 12-08-2023.
Dinas Kesehatan Banjarbaru. Satgas Covid-19 Kota Banjarbaru. 2022. https://corona.banjarbarukota.go.id. Accessed 12-08-2023.
Kementerian Kesehatan Republik Indonesia. Protokol Tata Laksana Covid-19 Edisi 2. 2021. https://kemkes.go.id/downloads/resources/download/info-terkini/Buku%20 Saku%20Protokol%20Kesehatan%20ep.%202%20rev%20final%20with%20page.pdf. Accessed 12-08-2023
Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bio Science Trends. 2020; 14(1): 72-73.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Res. 2020; 178.
Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3): 269-271.
Spinner CD, Gottlieb RL, Criner GJ et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11): 1048-1057.
Saleha, S., Sumiwi, S. A., Sanggelorang, J., & Leniawati, I. Review?: Efek Samping Dan Manajemen Obat Covid-19 Pada Gangguan Fungsi Ginjal Dan Hati. Farmaka, 2018; 16: 213–221
Fatima F, Qadeer F, Abidi A, Siddiqui Z, Rizvi DA and Ahmad A. A study of clinical outcome and safety profile of remdesivir in COVID-19 patients in a tertiary care centre. Al Ameen J Med Sci, 2022; 15(1): 32-37.
Welliver R, Monto AS, Carewicz O et al. Effectiveness of Oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001; 285: 748-754
Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. The Lancet Global Health. 2020. May 1; 8(5): e639-40.
Badan Pengawas Obat Dan Makanan Republik Indonesia. Informatorium Obat Covid-19 di Indonesia. Jakarta: Badan POM. 2020
Prisilia AP, Khusuma A, Getas IW. Pengaruh Lamanya Gejala Terhadap Hasil Pemeriksaan Albumin, Ureum Dan Kreatinin Pada Pasien UGD Positif COVID-19 Di Rumah Sakit Wira Bhakti Angkatan Darat. Journal of Indonesia Laboratory Students (JILTS). 2023 May 31; 2(1): 84-90.
Ozsurekci Y, Oygar PD, Gürlevik SL, Kesici S, Ozen S, Kurt Sukur ED, Gülhan B, Topaloglu R, Bayrakci B, Cengiz AB. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?. Pediatric Nephrology. 2021.Nov; 36(11): 3771-6.
